MASSDEVICE ON CALL — Aesthetic medical device maker Allergan (NYSE:AGN) will get a date with the FDA to review clinical data for the company’s Juv[eacute]derm Voluma XC dermal filler.

Allergan hopes to win indication for deep implantation for aesthetic restoration in the face, according to the FDA notice.

The FDA panel date is set for May 2, 2013, at which time the FDA’s General & Plastic Surgery Devices Panel will "discuss, make recommendations and vote on information related to the premarket approval application for the Juv[eacute]derm Voluma XC.”

California-based Allergan is coming off of another major FDA win. Last month the federal watchdog agency granted premarket approval for Allergan’s next-generation Natrelle silicon gel-filled breast implants.

Making catheters kid-friendly
Pediatric catheters placed into the large vein near the heart are 4 times less likely to dislodge compared with those inserted in the arm or leg, according to Johns Hopkins researchers.
Read more

BioSpectrum Asia names GI Dynamics’ weight-loss implant the "Product of the Year"
GI Dynamics (ASX:GID) won BioSpectrum Asia’s "Product of the Year" award for the EndoBarrier gastrointestinal liner, which aims to induce weight-loss and help control or even reverse symptoms of diabetes.
Read more

Prostatectomy outcome depends on the doc, researchers say
The outcomes of radical prostatectomy, especially with regard to future continence, may depend heavily on who performs the procedure, according to the European Assn. of Urology.
Read more